ISCOMATRIX™ vaccines: Safety in human clinical studies

Human Vaccines

Volumn 6, Issue 3, 2010, Pages 237-246

  McKenzie, Andrew ^a   Watt, Marli ^a   Gittleson, Charmaine ^a  

^a CSL LIMITED   (Australia)

Author keywords

Adjuvant; ISCOMATRIX; Safety; Vaccine

Indexed keywords

CYTOKINE; ISCOMATRIX VACCINE; PLACEBO; SAPONIN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANAPHYLAXIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEVER; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE REACTION; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DISEASE; MYALGIA; NAUSEA; PHARYNGITIS; PROPHYLAXIS; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SWEATING; SYSTEMIC DISEASE; SYSTEMIC REACTOGENICITY; VERRUCA VULGARIS;

EID: 77953647540     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.3.10754     Document Type: Review

References (29)

1. Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004; 22:3658-68.
2. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761-72.
3. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; Epub ahead of print.
4. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005; 105:2465-72.
5. Glauert A, Dingle JT, Lucy JA. Action of saponins on biological cell membranes. Nature 1962; 196:953-5.
6. Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM-Matrix. Vaccine 1995; 13:1375-82.
7. Soltysik S, Wu JY, Recchia J, Wheeler DA, Newman MJ, Coughlan RT, et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995; 13:1403-10.
8. Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. Bioch Biophys Acta 1995; 1241:117-38.
9. + T cell responses in humans. Proc Natl Acad Sci USA 2004; 101:10697-702.
10. Frazer IH, Quinn M, Nicklin J, Tan J, Perrin L, Ng P, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23:172-81.
11. Drane D, Pearse MJ. Chapter 12: The ISCOMATRIX™ adjuvant. In Schijns VE, O'Hagan DT, eds. Immunopotentiators in Modern Vaccines. Burlington MA: Elsevier Academic Press 2006; 191-216.
12. + T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers. Human Vaccines 2009; 5:151-7.
13. Anderson J, Hoy J, Hillman R, Barnden M, Eu B, McKenzie A, et al. A randomised, placebo-controlled, dose-escalation study to determine the safety, tolerability and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr 2009; 52:371-81.
14. Kenney RT, Edelman R. Survey of Human Use adjuvants. Expert Rev Vaccines 2003; 2:167-88.
15. Sesardic D, Rijpkema S, Patel BP. New adjuvants: EU regulatory developments. Expert Rev Vaccines 2007; 6:849-61.
16. Verstraeten T, Descamps D, David M-P, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8.
17. Simon JK, Edelman R. Chapter 18: Clinical evaluation of adjuvants. In Schijns VE, O'Hagan DT, eds. Immunopotentiators in Modern Vaccines. Burlington MA: Elsevier Academic Press 2006; 191-216.
18. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: What is the evidence? Lancet 2003; 362:1659-66.
19. Descotes J, Ravel G, Ruat C. Vaccine: predicting the risk of allergy and autoimmunity. Toxicology 2002; 174:45-51.
20. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007; 356:1928-43.
21. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007; 356:1915-27.
22. Paavonen J, Jenkins D, Bosch F, Naud P, Salmerón J, Wheeler C, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
23. Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008; 26:4160-7.
24. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59™ adjuvant. Vaccine 2008; 26:3209-22.
25. Transcripts from Public Workshop: Adjuvants and Adjuvanted Preventative and Therapeutic Vaccines in Infectious Disease Indications [document on the internet]. FDA 2009; [cited 2009]. Available from: http://www.fda.gov/ BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm095698.htm.
26. Pepys MB, Hirschfield GM. C-reactive protein - a critical update. J Clin Invest 2003; 111:1805-12.
27. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Path & Lab Med 2000; 124:71-81. (Pubitemid 30053777)
28. Xavier RM, Yamauchi Y, Nakamura M, Tanigawa Y, Ishikura H, Tsunematsu T, et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev 1995; 78:145-54.
29. Rüggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis and presentation of immunization safety data. Vaccine 2007; 25:5675-84.